AX 201
Alternative Names: AX201Latest Information Update: 30 Jul 2012
At a glance
- Originator SYGNIS Bioscience GmbH
- Class
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease; Stroke
Most Recent Events
- 25 Jul 2012 Discontinued - Preclinical for Parkinson's disease in Germany (unspecified route)
- 25 Jul 2012 Discontinued - Preclinical for Stroke in Germany (unspecified route)
- 12 Dec 2006 Preclinical development of AX 201 is still ongoing